Antonio Gasbarrini

ORCID: 0000-0002-6230-1779
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Helicobacter pylori-related gastroenterology studies
  • Microscopic Colitis
  • Liver Disease and Transplantation
  • Gut microbiota and health
  • Inflammatory Bowel Disease
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Celiac Disease Research and Management
  • Gastrointestinal motility and disorders
  • Eosinophilic Esophagitis
  • Hepatitis C virus research
  • Clostridium difficile and Clostridium perfringens research
  • Diet and metabolism studies
  • Gastroesophageal reflux and treatments
  • Digestive system and related health
  • Gastrointestinal disorders and treatments
  • Gastric Cancer Management and Outcomes
  • Organ Transplantation Techniques and Outcomes
  • Nutrition and Health in Aging
  • Hepatitis B Virus Studies
  • Pancreatic and Hepatic Oncology Research
  • Alcohol Consumption and Health Effects
  • COVID-19 Clinical Research Studies
  • Pancreatitis Pathology and Treatment
  • Liver physiology and pathology

Università Cattolica del Sacro Cuore
2016-2025

Agostino Gemelli University Polyclinic
2016-2025

Istituti di Ricovero e Cura a Carattere Scientifico
2003-2025

University of the Sacred Heart
2009-2025

Centro Clinico Nemo
2022-2025

Karolinska Institutet
2024

Universidade Estadual Paulista (Unesp)
2024

University of Palermo
2001-2024

Ahvaz Jundishapur University of Medical Sciences
2024

Istituto Nazionale per le Ricerche Cardiovascolari
2024

Important progress has been made in the management of Helicobacter pylori infection and this fifth edition Maastricht Consensus Report, key aspects related to clinical role H. were re-evaluated 2015. In V/Florence Conference, 43 experts from 24 countries examined new data five subdivided workshops: (1) Indications/Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) Gastric Microbiota. The results individual workshops presented a final consensus voting that included...

10.1136/gutjnl-2016-312288 article EN Gut 2016-10-05

The role played by the gut in nonalcoholic fatty liver disease (NAFLD) is still a matter of debate, although animal and human studies suggest that gut-derived endotoxin may be important. We investigated intestinal permeability patients with NAFLD evaluated correlations between this phenomenon stage disease, integrity tight junctions within small intestine, prevalence bacterial overgrowth (SIBO). examined 35 consecutive biopsy-proven NAFLD, 27 untreated celiac (as model hyperpermeability) 24...

10.1002/hep.22848 article EN Hepatology 2009-01-23

Faecal microbiota transplantation (FMT) is an important therapeutic option for <i>Clostridium difficile</i> infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with alteration gut microbiota. Although health community assessing renewed interest and patients are becoming more aware, there technical logistical issues establishing such non-standardised treatment into clinical practice safety proper governance. In view this,...

10.1136/gutjnl-2016-313017 article EN cc-by-nc Gut 2017-01-13

Helicobacter pylori Infection is formally recognised as an infectious disease, entity that now included in the International Classification of Diseases 11th Revision. This principle leads to recommendation all infected patients should receive treatment. In context wide clinical spectrum associated with gastritis, specific issues persist and require regular updates for optimised management. The identification distinct scenarios, proper testing adoption effective strategies prevention gastric...

10.1136/gutjnl-2022-327745 article EN Gut 2022-08-08

The gastrointestinal tract is a complex and dynamic network where an intricate mutualistic symbiosis modulates the relationship between host microbiota in order to establish ensure gut homeostasis. Commensal Clostridia consist of gram-positive, rod-shaped bacteria phylum Firmicutes make up substantial part total microbiota. They start colonize intestine breastfed infants during first month life populate specific region intestinal mucosa close with cells. This position allows them participate...

10.1186/1757-4749-5-23 article EN cc-by Gut Pathogens 2013-01-01

Acute-on-chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin dialysis with the molecular adsorbent recirculating system (MARS) decreases retained substances and improves hemodynamics hepatic encephalopathy (HE). However, its survival impact unknown. In all, 189 patients ACLF were randomized either to MARS (n=95) or standard therapy (SMT) (n=94). Ten (five per group) excluded due protocol violations. addition, 23 (MARS: 19; SMT: 4) from per-protocol (PP) analysis...

10.1002/hep.26185 article EN Hepatology 2012-12-05

The gut-liver axis plays a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is third leading cause hepatocellular carcinoma (HCC) worldwide. However, link between gut microbiota and hepatocarcinogenesis remains to be clarified. aim this study was explore what features are associated with HCC patients cirrhosis NAFLD. A consecutive series NAFLD-related (group 1, 21 patients), without 2, 20 healthy controls 3, patients) studied for profile, intestinal...

10.1002/hep.30036 article EN Hepatology 2018-04-17

Summary Background Faecal microbiota transplantation ( FMT ) from healthy donors is considered an effective treatment against recurrent Clostridium difficile infection. Aim To study the effect of via colonoscopy in patients with C. infection compared to standard vancomycin regimen. Methods In open‐label, randomised clinical trial, we assigned subjects receive: , short regimen (125 mg four times a day for 3 days), followed by one or more infusions faeces colonoscopy; 125 daily 10 days,...

10.1111/apt.13144 article EN Alimentary Pharmacology & Therapeutics 2015-03-01

VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point study was to assess effects supplementation with patients affected by relapsing ulcerative colitis (UC) who are already under 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses.A total 144 consecutive were randomly treated for 8 weeks dose 3,600 billion CFU/day (71 patients) or placebo (73 patients).In all, 65 group and 66 completed study. decrease...

10.1038/ajg.2010.218 article EN cc-by-nc-nd The American Journal of Gastroenterology 2010-06-01

Summary Background Aminosalicylates are the mainstay of therapy to prevent relapse quiescent ulcerative colitis. The rationale for using probiotics is based on evidence implicating intestinal bacteria in pathogenesis this disorder. Aim To evaluate efficacy Lactobacillus GG alone or combination with mesalazine vs. as maintenance treatment Patients and methods 187 colitis patients disease were randomized receive 18 × 10 9 viable bacteria/day (65 patients), 2400 mg/day (60 patients) + (62...

10.1111/j.1365-2036.2006.02927.x article EN Alimentary Pharmacology & Therapeutics 2006-05-12

10.1016/s0140-6736(18)30840-7 article EN The Lancet 2018-06-01
Coming Soon ...